News

Altimmune Shares Groundbreaking Results on Pemvidutide Therapy

Altimmune Shares Groundbreaking Results on Pemvidutide Therapy

Altimmune Reveals Promising Data from Recent Clinical Trials

Recently, Altimmune, Inc. (Nasdaq: ALT), a pioneering biopharmaceutical company focusing on innovative peptide-based therapies for liver and cardiometabolic issues, published exciting findings from its ongoing IMPACT Phase 2b trial in The Lancet. This publication shares 24-week results that highlight both the efficacy and safety of pemvidutide in treating metabolic dysfunction-associated steatohepatitis (MASH).

Significant Findings in MASH Treatment

The trial results demonstrate noteworthy advancements, including substantial resolutions of MASH, marked weight loss, and a favorable side effect profile for patients. As a dual glucagon/GLP-1 agonist, pemvidutide targets both the metabolic and hepatic aspects of this complex condition.

IMPACT Phase 2b Trial Overview

This randomized, double-blind trial enrolled 212 participants diagnosed with biopsy-confirmed MASH. Two specific dosage regimens were evaluated: 1.2 mg and 1.8 mg of pemvidutide, compared to a placebo over a 24-week period. The primary efficacy endpoints focused on MASH resolution without worsening fibrosis, which was significantly achieved in participants receiving pemvidutide.

Clinical Impact of Pemvidutide

Dr. Mazen Noureddin, the trial's principal investigator, expressed great enthusiasm regarding the findings. He emphasized that reversing liver fibrosis is paramount for preventing severe health risks such as cirrhosis. The observed improvements after just 24 weeks reveal the potential impact of pemvidutide on long-term health outcomes for MASH patients.

Results and Key Indicators

Among the critical outcomes were impressive reductions in liver fat and inflammation. The data reflected strong evidence of improved liver function markers, including various non-invasive tests. For instance, the results revealed:

  • MASH resolution rates of 58% for the 1.2 mg group and 52% for the 1.8 mg group, compared to 20% in the placebo group.
  • A decrease in body weight by an average of 4.8% in the 1.2 mg group and 5.8% in the 1.8 mg group, showcasing the medication's role in weight management.
  • A remarkable normalization of liver fat content by 31% and 44% respectively in the treatment groups.

Safety Profile of Pemvidutide

Notably, the safety results were encouraging, with very few serious adverse events reported during the trial. This is crucial, especially when considering patient compliance and treatment sustainability. The dual mechanism of action inherent to pemvidutide might be significant in addressing both the metabolic and fibrotic components of liver disease.

Next Steps for Altimmune

With the substantial success reflected in the present study, Altimmune is excited about the future potential of pemvidutide. The company plans to present these findings in a late-breaking session at The Liver Meeting® 2025, furthering awareness and discussion around MASH treatments.

Future Trials and Developments

Altimmune is not stopping here. The company anticipates additional findings related to longer-term outcomes from the IMPACT trial to be shared in the upcoming quarters. With ongoing trials in alcohol use disorder and other related diseases, Altimmune aims to create a robust portfolio of therapeutic options.

About Altimmune

As a late clinical-stage biopharmaceutical company, Altimmune emphasizes its commitment to developing novel treatments for liver diseases and related metabolic disorders. Their lead candidate, pemvidutide, represents a thoughtful approach to addressing MASH and highlights the innovative spirit driving the company’s mission.

Frequently Asked Questions

What does pemvidutide treat?

Pemvidutide is being developed for treating metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).

What were the main findings of the IMPACT Phase 2b trial?

The trial showed significant improvement in MASH resolution, weight loss, and reductions in liver fat and inflammation following pemvidutide treatment.

What is the safety profile of pemvidutide?

The safety analysis indicated few serious adverse events, suggesting good tolerability among participants using pemvidutide in clinical settings.

When will more results from the IMPACT trial be shared?

Additional findings, including longer-term outcomes, are expected to be reported in the near future, with discussions ongoing through 2025.

How can I learn more about Altimmune's developments?

For the latest updates on Altimmune and its product developments, you can visit their official website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 118

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 100

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 76

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading
Franklin County Trees Raise Funds and Honor Veterans

Updated Category News Views 66

Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 89

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 87

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 50

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading

Top 5 Most Recently Viewed Articles

Sigenergy Embraces AI in Smart Energy Solutions at Intersolar

Updated Category News Views 284

Sigenergy's Vision for Smart Energy Sigenergy recently showcased its dedication to innovative, AI-driven energy solutions during a major event at Intersolar 2025. This milestone reinforced the company's mission to develop a user-centered smart energy ecosystem. With over 500 attendees, the launch at Brainlab Tower highlighted Sigenergy's ambitious goal of redefining...

Continue Reading
Investor Insights on Charter Communications Earnings Report

Updated Category News Views 181

Anticipation Surrounding Charter Communications Earnings Charter Communications (NASDAQ: CHTR) is set to unveil its quarterly earnings in the near future. Investors are particularly eager to see if the company can surpass previous estimates and provide favorable outlooks for the upcoming quarters. Recent trends suggest that beat expectations could lead to positive stock...

Continue Reading
Intevac Welcomes Kevin Barber as New Chairman of the Board

Updated Category News Views 362

Intevac got hit with a leadership shakeup back in early 2024 when Kevin Barber took the reins as the new Board Chairman, stepping into some big shoes after David Dury. Traders were buzzing—who wouldn’t be? Dury had been at the helm since 2017, steering Intevac through several crucial transitions. But Barber's appointment felt like a fresh shot of adrenaline for...

Continue Reading
Insight Into the Growing Market for Display Cases Worldwide

Updated Category News Views 63

The Growing Popularity of Display Cases in Global Markets As retail continues to evolve, display cases have become essential for attracting customers. Their visual appeal significantly affects buying choices, leading businesses to invest in high-quality display options. Recent research shows that the demand for display cases is on the rise, with an expected annual growth...

Continue Reading
Medallion Secures $43 Million to Innovate Healthcare Credentialing

Updated Category News Views 347

Medallion Announces Major Funding to Revolutionize Credentialing Medallion has successfully raised $43 million to further develop its innovative AI-driven platform and to launch CredAlliance™, a groundbreaking credentialing clearinghouse aimed at streamlining provider onboarding and verification processes. Empowering Healthcare with Intelligent Automation With this new...

Continue Reading